Kazi S, Prasad S, Pollak R, Holzer T, Heynen C, Fabrega A J, Pitrak D, Layden T J
Department of Medicine, University of Illinois at Chicago 60612-7213.
Dig Dis Sci. 1994 May;39(5):961-4. doi: 10.1007/BF02087544.
The hepatitis C virus (HCV) may be an important cause of chronic liver disease in renal transplant recipients. We investigated retrospectively the incidence and outcome of HCV infection in long-term renal transplant recipients and patients on hemodialysis. Stored, pretransplant sera of transplant recipients with normal liver biochemistry at surgery were tested for hepatitis C by a second-generation enzyme immunoassay. Hemodialysis patients were tested by a first-generation enzyme-linked immunosorbent assay (ELISA) against c100-3. We studied 252 renal transplant recipients and 58 hemodialysis patients followed for 65 +/- 10 months and 26 +/- 6 months, respectively. Fifteen percent (38/252) of the transplant recipients were HCV positive as were 3/58 (5%) of the hemodialysis patients. Overt liver disease occurred in 22/252 (8.7%) transplant recipients and none in the hemodialysis group. Thirty-six percent (8/22) of transplant recipients with overt liver disease were HCV positive. No HCV-positive patients died of liver failure. Of six biopsies in the HCV-positive transplant group, two had histological evidence of CAH. CAH was seen in six of eight biopsies in the HCV-negative transplants and two of these latter patients progressed to cirrhosis. No hemodialysis patients had clinical or histological evidence of chronic liver disease. Two HCV-negative transplant patients died of liver failure, while no deaths related to liver disease occurred in hemodialysis patients regardless of HCV status. We conclude that hepatitis C may cause chronic hepatitis in renal transplant patients.(ABSTRACT TRUNCATED AT 250 WORDS)
丙型肝炎病毒(HCV)可能是肾移植受者慢性肝病的一个重要病因。我们回顾性调查了长期肾移植受者和血液透析患者中HCV感染的发生率及转归情况。对手术时肝脏生化指标正常的移植受者术前储存血清采用第二代酶免疫法检测丙型肝炎。血液透析患者采用第一代酶联免疫吸附测定(ELISA)检测抗c100-3。我们研究了252例肾移植受者和58例血液透析患者,随访时间分别为65±10个月和26±6个月。15%(38/252)的移植受者HCV阳性,血液透析患者中3/58(5%)HCV阳性。22/252(8.7%)的移植受者出现显性肝病,血液透析组无显性肝病发生。显性肝病的移植受者中36%(8/22)HCV阳性。无HCV阳性患者死于肝功能衰竭。HCV阳性移植组6例活检中,2例有慢性活动性肝炎(CAH)的组织学证据。HCV阴性移植组8例活检中有6例出现CAH,其中2例进展为肝硬化。无血液透析患者有慢性肝病的临床或组织学证据。2例HCV阴性移植患者死于肝功能衰竭,无论HCV状态如何,血液透析患者均未发生与肝病相关的死亡。我们得出结论,丙型肝炎可能导致肾移植患者发生慢性肝炎。(摘要截短至250字)